



# Q1FY26E Pharmaceuticals Sector Preview



## Pharmaceuticals

### Revenue to grow steadily, led by India and Emerging Markets

#### COVERAGE STOCKS

Company name	Rating	CMP	Target price	Upside
Granules India (GRAN)	BUY	493	612	24.1%
Lupin (LPC)	BUY	1,979	2,453	24.0%
Supriya Lifescience (SUPRIYA)	BUY	714	843	18.1%
Zydus Lifesciences (ZYDUSLIF)	BUY	999	1,069	7.0%
Glenmark Pharmaceuticals (GNP)	BUY	1,860	1,650	-11.3%
Aurobindo Pharmaceuticals (ARBP)	ACCUMULATE	1,185	1,320	11.4%
Divi's Laboratories (DIVI)	ACCUMULATE	6,888	7,518	9.1%
Sun Pharmaceutical Industries (SUNP)	ACCUMULATE	1,680	1,811	7.8%
Cipla (CIPLA)	ACCUMULATE	1,510	1,593	5.5%
Dr. Reddy's Laboratories (DRRD)	ACCUMULATE	1,310	1,324	1.1%
Alembic Pharmaceuticals (ALPM)	ACCUMULATE	1,002	986	TA*
Laurus Labs (LAURUS)	ACCUMULATE	776	687	TA*

#### Price Performance

	Close	1M (%)	YTD (%)
Nifty	25,461	1.83%	7.2%
Sensex	83,442	1.5%	6.3%
USD / INR	85.7550	0.0%	+0.1%

Note: TP and recommendation have been retained from previous update reports; we will review it post detailed Q1FY26E results analysis and conference call of the said companies. Source: NSE; Data as of July 07<sup>th</sup>, 2025: \*TA stands for Target Achieved

#### Q1FY26E outlook strong for domestic pharma; coverage universe to benefit from superior execution and product launch

- As per Pharma rack data, during Apr'25, the Indian pharmaceutical market (IPM) grew by 7.8% YoY, led by improved price realization (+5.1% YoY), modest new launches (+2.3% YoY), and muted volume growth (+0.4% YoY).
- During May'25, the Indian pharmaceutical market (IPM) grew 7.2% YoY, driven by improved price realization of (+5.0% YoY), new launches (+2.2% YoY) and flat volume growth.
- During Apr'25, cardiac, respiratory, and neuro/CNS therapies outperformed overall IPM growth whereas anti-infectives, gynecology, and anti-diabetes segments underperformed, while during May'25 cardiac, respiratory, anti-infectives therapies outperformed overall IPM growth whereas gastro, vitamins, and dermatology segments underperformed the overall growth.
- We expect the domestic business to deliver high single-digit growth in Q1FY26E and sustain its momentum into FY26E. Our coverage companies are expected to beat market growth ranging from 8.0% to 12.0% in Q1FY26E.
- Glenmark Pharma would witness highest revenue growth driven by recent product launches across diabetes and upcoming oncology assets such as Tislelizumab, Zanubrutinib. Lupin is expected to return to double-digit growth with new launches scale up.

#### Indian pharma braces for muted US growth amid regulatory and pricing overhang

- Although the threat of US tariffs on Indian pharmaceutical imports has created uncertainty and market volatility, so far, the sector has been largely exempted, as it plays a critical role in the US healthcare.
- However, the risk lingers on companies specifically with higher US exposure. India and the US are engaged in negotiations, and the long-term outlook will depend on the evolution of trade policies and the ability of Indian pharma to adapt and diversify.
- During Q1FY26E, most of the coverage companies are expected to observe single-digit growth in their US geography. Revlimid contribution mix is expected to reduce in FY26E; as US API tariffs and generic pricing pressure may weigh on margins despite mitigation efforts.

#### Coverage companies to post strong EM/ROW and Europe growth on portfolio strength

- Indian pharma companies are expected to witness robust growth across emerging markets in Q1FY26E, with revenue expansion aided by increase in demand for generics, chronic therapies, and new product launches.

## Pharmaceuticals

### SECTOR OVERVIEW



- During Q1FY26E, our coverage companies are expected to observe strong double-digit growth in their EM geography, led by recovery across Mexico and sustained momentum across South Africa, Brazil, and the Philippines, driven by market diversification and deeper regional partnerships.
- Europe segment is expected to witness strong double-digit growth for our coverage companies. The growth is anticipated to be aided by strong momentum in branded respiratory and dermatology portfolios, driven by upcoming new product launches.

#### Coverage companies to post high single digit revenue growth but slight contraction in profitability margin

- In Q1FY26E, we anticipate high single digit revenue growth (YoY) from the pharma companies in our coverage. The revenue is expected to grow at 9.8% YoY (+3.1% QoQ), led by strong traction in domestic formulations, a rebound in emerging markets, ramp-up of complex generics, and accelerating contributions from CDMO/custom synthesis.
- Stronger growth is anticipated from Supriya Lifescience led by expansion in CDMO segment, Divis Laboratories led by robust growth across generic API and Custom Synthesis segment, and Laurus Labs led by stronger growth across CDMO and Custom Synthesis, and higher growth momentum in Generic FDF.
- EBITDA is expected to grow at 7.3% YoY (+5.2% QoQ), while the EBITDA margin is expected to contract by 57bps YoY (+52 bps QoQ), due to poor operating leverage, pricing pressure across the US, and higher base effect across selected companies, partially offset by expansion in gross margins and improved operational efficiencies.
- We anticipate Supriya Lifesciences and Zydus Lifesciences to observe contraction in EBITDA margins led by higher base effect and scale-up in lower-margin and semi-regulated markets.
- Laurus Labs, Divis Laboratories, and Alembic Pharma are expected to witness stronger expansion of EBITDA margins led by improved operating leverage, favorable product mix, and higher capacity utilization.
- Adjusted net profit for companies under coverage is expected to grow at 4.5% YoY (+3.9% QoQ), while the Adjusted net margin is expected to contract by 84bps YoY (+13 bps QoQ), led by contraction in EBITDA margins.

#### Valuation

- Nifty Pharma is currently trading at 30.2x FY26E P/E, nearly its 3-year average NTM P/E. We believe the sector has priced in majority of the risks on the US front and should perform well, once the tariff uncertainty looms away. We expect upside potential would be stock-specific, led by stronger domestic growth, new product launches and expansion across geographies.
- Laurus Labs (positive outlook with robust pipeline), Supriya Lifesciences (consistent revenue and profit growth), and Divi's Labs (strong margin growth led by commercialization of Custom Synthesis contracts) remains our top pick in the pharma sector.**



Source: Bloomberg, Deven Choksey Research

#### ANALYST


 Ishank Gupta, [fundamental-research2@devenchoksey.com](mailto:fundamental-research2@devenchoksey.com) +91-22-6696 5519

Phone: +91-22-6696 5555 | Ext - 519


[www.devenchoksey.com](http://www.devenchoksey.com)

Pharmaceuticals

Price Performance Charts



Source: Bloomberg, Deven Choksey Research



Source: NSE, DevenChoksey Research

## Pharmaceuticals

### Exhibit 1: Quarterly result expectation for companies under coverage

INR Mn

Q1FY26E	Outperform	Base	Underperform	View
Sun Pharma				
Sales	142,177	137,116	134,586	<ul style="list-style-type: none"><li>We expect revenue to grow by 8.4% YoY (5.8% QoQ) driven by focus on expanding its specialty portfolio in dermatology and oncology, high single digit growth in domestic market where they have a market leadership. Additionally, an increase in branded generics share from EM business will contribute growth</li><li>EBITDA margin is expected to contract by 44bps YoY (+204bps QoQ) to 28.5%, due to poor operating leverage driven by elevated other expenses.</li><li>Adjusted net margin is expected to contract by 197bps YoY (+370bps QoQ) to 20.8%, due to weaker operational performance, coupled with increase in effective tax rate in Q1FY26E to 22.0%, compared to 16.1% in Q1FY25.</li></ul>
EBITDA	41,614	39,036	37,912	
Adj. PAT	31,049	28,572	27,507	
EBITDA (%)	29.3%	28.5%	28.2%	
Adj. NPM (%)	21.8%	20.8%	20.4%	
Cipla				
Sales	74,466	71,788	70,450	<ul style="list-style-type: none"><li>We expect revenue to grow by 7.2% YoY (+6.7% QoQ), led by the launch of key respiratory brands and a robust pipeline of peptide assets. We anticipate that Company's strategic focus on complex generics and long-acting injectables will drive steady long-term growth. Overall, the domestic business is expected to outperform the market during Q1FY26E.</li><li>EBITDA margin is expected to contract by 148bps YoY (+131bps QoQ) to 24.2%, led continued pricing pressure in the US.</li><li>Adjusted net margin is expected to contract by 84bps YoY (-140bps QoQ) to 16.8%, led by weaker operational performance.</li></ul>
EBITDA	18,285	17,341	16,876	
Adj. PAT	12,847	12,026	11,661	
EBITDA (%)	24.6%	24.2%	24.0%	
Adj. NPM (%)	17.3%	16.8%	16.6%	
Dr. Reddy's Lab				
Sales	90,709	88,400	84,552	<ul style="list-style-type: none"><li>We expect revenue to grow by 14.9% YoY (+3.7% QoQ) aided by a combination of organic growth, strategic acquisitions, and new product launches. The management has guided for sustained double-digit growth. Additionally, a strong ramp-up in the Indian business and improving volume momentum in Emerging Markets are expected to further bolster overall performance.</li><li>EBITDA margin is expected to contract by 141bps YoY (+195bps QoQ) to 26.3%, led by unfavorable product mix and increase in operating expenses.</li><li>Adjusted net margin is expected to contract by 43bps YoY (-192bps QoQ) to 17.7%, led by weaker operational performance.</li></ul>
EBITDA	24,015	23,227	21,708	
Adj. PAT	16,208	15,618	14,431	
EBITDA (%)	26.5%	26.3%	25.7%	
Adj. NPM (%)	17.9%	17.7%	17.1%	

## Pharmaceuticals

### Exhibit 1: Quarterly result expectation for companies under coverage

INR Mn

Q1FY26E	Outperform	Base	Underperform	View
Zydus Lifesciences				
Sales	72,573	69,469	68,227	<ul style="list-style-type: none"><li>We expect revenue to grow by 11.9% YoY (6.4% QoQ) led by strong growth in India and international markets, along with scaling up new growth themes like biologics and vaccines. India formulations- expected to continue outperform the Indian pharmaceutical market, led by innovation and volume growth.</li><li>EBITDA margin is expected to contract by 597bps YoY (-515bps QoQ) to 28.0%, due to higher base.</li><li>Adjusted net margin is expected to contract by 532bps YoY (-395bps QoQ) to 18.0%, led by weaker operational performance.</li></ul>
EBITDA	21,054	19,459	18,975	
Adj. PAT	13,758	12,475	12,116	
EBITDA (%)	29.0%	28.0%	27.8%	
Adj. NPM (%)	19.0%	18.0%	17.8%	
Divis' Labs				
Sales	25,926	25,290	24,231	<ul style="list-style-type: none"><li>We expect revenue to grow by 19.4% YoY (-2.2% QoQ), driven by robust order pipelines in both the generic API and Custom Synthesis (CS) segments, as the management has guided for strong double-digit growth.</li><li>EBITDA margin is expected to expand by 363bps YoY (-127bps QoQ) to 33.0%, led by expansion in gross margins supported by backward integration, improved product mix, and operational efficiencies. The ramp-up of Kakinada Unit III is also likely to enhance cost efficiencies and mitigate raw material price volatility.</li><li>Adjusted net margin is expected to expand by 486bps YoY (-45bps QoQ) to 25.2%, led by stronger operational performance.</li></ul>
EBITDA	8,685	8,346	7,948	
Adj. PAT	6,653	6,364	6,049	
EBITDA (%)	33.5%	33.0%	32.8%	
Adj. NPM (%)	25.7%	25.2%	25.0%	
Lupin				
Sales	60,446	57,646	57,086	<ul style="list-style-type: none"><li>We expect revenue to grow modestly by 2.9% YoY (1.7% QoQ) driven by growth in India and Rest of the World markets, partially offset by slower growth in the US due to tariffs uncertainty.</li><li>EBITDA margin is expected to expand by 95bps YoY (+112bps QoQ) to 23.9%, as the share of complex generics and specialty products increases in the overall revenue mix.</li><li>Adj. PAT margin is expected to contract 54bps YoY (+146bps QoQ) to 14.6%, led by improved operational performance.</li></ul>
EBITDA	14,763	13,791	13,542	
Adj. PAT	9,114	8,404	8,208	
EBITDA (%)	24.4%	23.9%	23.7%	
Adj. NPM (%)	15.1%	14.6%	14.4%	



## Pharmaceuticals

### Exhibit 1: Quarterly result expectation for companies under coverage

INR Mn

Q1FY26E	Outperform	Base	Underperform	View
Aurobindo Pharma				
Sales	84,011	81,741	80,227	<ul style="list-style-type: none"><li>We expect revenue to grow by 8.0% YoY (-2.5% QoQ) driven by growth in Europe and other geographies which will partially offset by slow growth in the US due to absence of new product launches.</li><li>EBITDA margin is expected to contract by 40bps YoY (-38bps QoQ) to 21.0%, led by contraction in gross margins, impacted by slower growth driven by pending FDA clearance of Eugia Unit III.</li><li>Adjusted net margin is expected to contract by 73bps YoY (+64bps QoQ) to 11.4%, due to weaker operational performance.</li></ul>
EBITDA	18,062	17,166	16,447	
Adj. PAT	10,014	9,334	8,760	
EBITDA (%)	21.5%	21.0%	20.5%	
Adj. NPM (%)	11.9%	11.4%	10.9%	
Glenmark Pharma				
Sales	37,641	36,667	35,045	<ul style="list-style-type: none"><li>We expect revenue to grow by 13.0% YoY (12.6% QoQ) driven by strong double-digit growth in India with recent launches of Empagliflozin, Sitagliptin, and Liraglutide (Lirafit) to support recovery in the diabetes portfolio. Additionally, Europe continues to show strong momentum, supported by branded respiratory and dermatology portfolios.</li><li>EBITDA margin is expected to expand by 146bps YoY (+236bps QoQ) to 19.6%, due to higher expansion in gross margin and favorable product mix.</li><li>Adj. PAT margin is expected to expand 166bps YoY (+55bps QoQ) to 12.1%, led by stronger operational performance.</li></ul>
EBITDA	7,487	7,184	6,691	
Adj. PAT	4,684	4,453	4,081	
EBITDA (%)	19.9%	19.6%	19.1%	
Adj. NPM (%)	12.4%	12.1%	11.6%	
Laurus Labs				
Sales	14,005	13,646	13,168	<ul style="list-style-type: none"><li>We expect revenue to grow by 14.2% YoY (-20.7% QoQ), driven by robust growth in the Custom Synthesis and Generic FDF segment. CDMO is positioned as the key growth engine, supported by an expanding pipeline, deeper integration with Big Pharma, and maturing commercial programs.</li><li>EBITDA margin is expected to expand by 937bps YoY (-75bps QoQ) to 23.7%, led by significant improvement in operational performance and favorable product mix.</li><li>Adjusted net margin is expected to expand by 842bps YoY (-411bps QoQ) to 9.5%, led by stronger operational performance.</li></ul>
EBITDA	3,375	3,234	3,095	
Adj. PAT	1,382	1,292	1,220	
EBITDA (%)	24.1%	23.7%	23.5%	
Adj. NPM (%)	9.9%	9.5%	9.3%	

## Pharmaceuticals

### Exhibit 1: Quarterly result expectation for companies under coverage





INR Mn

Q1FY26E	Outperform	Base	Underperform	View
Alembic Pharma				
Sales	17,781	17,156	16,688	<ul style="list-style-type: none"><li>We expect revenue to grow by 9.9% YoY (-3.1% QoQ) led by mid-teen growth in the US segment driven by a strong pipeline of new product launches and ongoing capacity expansion. The ex-US segment is expected to deliver double-digit growth, supported by broader market diversification and strengthened partnerships across key regions.</li><li>EBITDA margin is expected to expand by 260bps YoY (+240bps QoQ) to 17.8%, led by higher capacity utilization, cost control measures, and operating leverage.</li><li>Adjusted net margin is expected to expand by 127bps YoY (+102bps QoQ) to 9.9%, led by strong operating performance.</li></ul>
EBITDA	3,265	3,048	2,915	
Adj. PAT	1,864	1,696	1,599	
EBITDA (%)	18.4%	17.8%	17.5%	
Adj. NPM (%)	10.5%	9.9%	9.6%	
Granules				
Sales	12,697	12,461	12,107	<ul style="list-style-type: none"><li>We expect revenue to grow by 5.6% YoY (+4.1% QoQ), as impacted by regulatory risk from the FDA. Formulation and Intermediate segment growth will be partially offset by decline in API segment growth.</li><li>EBITDA margin is expected to contract by 11bps YoY (+79bps QoQ) to 21.9%, led by poor operating leverage driven by elevated operating expenses related to FDA remediation.</li><li>Adjusted net margin is expected to contract by 46bps YoY (-174bps QoQ) to 11.0%, due to weaker operational performance.</li></ul>
EBITDA	2,839	2,724	2,623	
Adj. PAT	1,454	1,365	1,302	
EBITDA (%)	22.4%	21.9%	21.7%	
Adj. NPM (%)	11.5%	11.0%	10.8%	
Supriya Lifesciences				
Sales	1,962	1,930	1,881	<ul style="list-style-type: none"><li>We expect revenue to grow by robust 20.1% YoY (4.8% QoQ) driven by ramp-up of DSM-Firmenich strategic contract, scaleup of CDMO segment and commercialization of Ambernath formulation facility. Additionally, new product launched during FY25 especially in anesthetic segment would start contributing meaningful revenue going forward.</li><li>EBITDA margin is expected to contract by 594bps YoY (-371bps QoQ) to 33.0%, led by higher base. The company has guided for a lower margin because of the scaleup of new products in semi-regulated markets with lower margin profile.</li><li>Adjusted net margin is expected to contract by 434bps YoY (-391bps QoQ) to 23.5%, led by weaker operational performance.</li></ul>
EBITDA	667	637	617	
Adj. PAT	480	453	437	
EBITDA (%)	34.0%	33.0%	32.8%	
Adj. NPM (%)	24.5%	23.5%	23.3%	



## Pharmaceuticals





### Valuation Charts



Source: Bloomberg, Deven Choksey Research

## Pharmaceuticals




### Valuation Charts



Source: Bloomberg, Deven Choksey Research

# Pharmaceuticals

## Valuation Charts



## Pharmaceuticals

Rating Legend (Expected over a 12-month period)	
Our Rating	Upside
Buy	More than 15%
Accumulate	5% – 15%
Hold	0 – 5%
Reduce	-5% – 0
Sell	Less than – 5%

### ANALYST CERTIFICATION:

I, **Ishank Gupta** (CA), Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect my views about the subject issuer(s) or securities. I also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

### Terms & Conditions and other disclosures:

DRChoksey FinServ Private Limited (hereinafter referred to as DCFPL) is a registered member of SEBI as a Research Entity vide Registration No. INH000011246 under SEBI (Research Analyst) Regulations, 2014, Portfolio Managers Entity vide Registration No. INP000007906 under SEBI (PORTFOLIO MANAGERS) Regulations, 2020 & Investment Adviser Entity vide Registration No. INA000017903 under SEBI (INVESTMENT ADVISERS) REGULATIONS, 2013.

The information and opinions in this report have been prepared by DCFPL and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of DCFPL. While we would endeavor to update the information herein on a reasonable basis, DCFPL is not under any obligation to update the information. Also, there may be regulatory, compliance or other reasons that may prevent DCFPL from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or DCFPL policies, in circumstances where DCFPL might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. DCFPL will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. DCFPL accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Our employees in sales and marketing team, dealers and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed herein, in reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

We submit that no material disciplinary action has been taken on DCFPL and its associates (Group Companies) by any Regulatory Authority impacting Equity Research Analysis activities.

DCFPL prohibits its associate, analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analyst covers.

DCFPL or its associates (Group Companies) collectively or its research analyst, or relatives do not hold any financial interest/beneficial ownership of more than 1% (at the end of the month immediately preceding the date of publication of the research report) in the company covered by Analyst, and has not been engaged in market making activity of the company covered by research analyst.

It is confirmed that, I, **Ishank Gupta** Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months. Compensation of our Research Analysts is not based on any specific brokerage service transactions.

DCFPL or its Associates (Group Companies) have not managed or co-managed public offering of securities for the subject company in the past twelve months.

DCFPL or its associates (Group Companies) collectively or its research analyst, or relatives might have received any commission/compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of brokerage services or specific transaction or for products and services other than brokerage services.

DCFPL or its associates (Group Companies) collectively or its research analyst, or relatives might have received any commission/compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report other than investment banking or merchant banking or brokerage services from the subject company.

DCFPL encourages the practice of giving independent opinion in research report preparation by the analyst and thus strives to minimize the conflict in preparation of research report. DCFPL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither DCFPL nor Research Analysts his associate or his relative, have any material conflict of interest at the time of publication of this report.

It is confirmed that **Ishank Gupta**, Research Analyst do not serve as an officer, director or employee of the companies mentioned in the report.

DCFPL or its associates (Group Companies) or its research analyst has may been engaged in market making activity for the subject company.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other Jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject DCFPL and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform them of and to observe such restriction.

The securities quoted are for illustration only and are not recommendatory.

DCFPL (Research Entity) and its research analysts uses Artificial Intelligence tools.

DCFPL and or its Research analysts shall be solely responsible for the security, confidentiality and integrity of the client data, use of any other information or data for research services, research services based on output of Artificial Intelligence tools and compliance with any law for the time being in force.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other Jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject DCFPL and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform them of and to observe such restriction.

Investment in securities are subject to market risks, read all the documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Please send your feedback to [research.retail@devenchoksey.com](mailto:research.retail@devenchoksey.com)

DRChoksey FinServ Private Limited

CIN Number -U67100MH2020PTC352816

**Registered Office and Corporate Office:**

5th Floor Abhishek Building, Behind Monginis Cake Factory, Off New Link Road, Andheri West, Mumbai-400058